Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapyTo the Editor:We read with interest the study by El Messaoudi et al. 1 analyzing and mathematically modeling serum HDV RNA and biochemical (ALT) kinetics during therapy with the entry inhibitor bulevirtide (BLV) alone or in combination with pegylated interferon (Peg-IFN).The authors analyzed an impressive amount of kinetic data from 183 treated patients (114 BLV; 69 BLV+Peg-IFN) who participated in two French multicenter cohort studies.They used a mathematical model to estimate BLV efficacy in blocking infection (parameter g) and viral and host kinetic parameters,
Authors
- Scott J. Cotler (ORCID: https://orcid.org/0000-0003-2564-7786)
- Harel Dahari (ORCID: https://orcid.org/0000-0002-3357-1817)
- Ori Wasserman
- Pietro Lampertico (ORCID: https://orcid.org/0000-0002-1026-7476)
- Adquate Mhlanga
Institutions
- University of Milan (IT)
- Loyola University Chicago (US)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Ospedale Maggiore (IT)
Publication Details
- Journal
- JHEP Reports
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1016/j.jhepr.2024.101211
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- Milliman
- Ministero della Salute
- National Institutes of Health